PD0325901, a selective MEK1 inhibitor - also used in our experiments - was proved to be effective in several preclinical models investigating malignant melanoma and papillary thyroid carcinoma[26, 27] and was already investigated in three clinical trials. This evidence concerns the gene MAP2K1 and melanoma.